Can fast-growing Eliquis overtake J&J’s Xarelto? Bristol’s execs think so

Carly Helfand

, a new-age anticoagulant that once dragged well behind analysts' expectations, has rocketed to the top of Bristol-Myers Squibb's sales charts. And company don't expect it to stop there.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS